2019
Prospective multicenter study to evaluate capsule endoscopy competency using a validated assessment tool
Rajan E, Martinez M, Gorospe E, Al Bawardy B, Dobashi A, Mara KC, Hansel SL, Bruining DH, Murray JA, Leggett CL, Nehra V, Iyer PG, Pasha SF, Leighton JA, Shiff AD, Gurudu SR, Raffals LE, Lavey C, Katzka DA, Chen CH. Prospective multicenter study to evaluate capsule endoscopy competency using a validated assessment tool. Gastrointestinal Endoscopy 2019, 91: 1140-1145. PMID: 31883863, DOI: 10.1016/j.gie.2019.12.024.Peer-Reviewed Original ResearchPatient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study
Al-Bawardy B, Kamboj AK, Desai S, Gorospe E, Bruining DH, Gostout CJ, Hansel SL, Larson MV, Murray JA, Nehra V, Leggett CL, Szarka LA, Watson RE, Rajan E. Patient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study. Scandinavian Journal Of Gastroenterology 2019, 54: 662-665. PMID: 31034255, DOI: 10.1080/00365521.2019.1608465.Peer-Reviewed Original ResearchConceptsPatient-oriented educationVideo capsule endoscopyCapsule passageWB groupCapsule retentionProcedure-related risksSignificant differencesLack of visualizationBACKGROUND/Information bookletPatientsVerbal educationCapsule endoscopyStudy teamWrist bandInterventionGroupStatusPOE groupEndoscopyPoor indicatorAid interventionsDifferences
2018
Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 2018, 24: 2272-2277. PMID: 29718223, DOI: 10.1093/ibd/izy133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBiological TherapyColitis, UlcerativeCrohn DiseaseFemaleFollow-Up StudiesGastrointestinal AgentsHumansInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisPrognosisProspective StudiesRetrospective StudiesTreatment OutcomeTuberculin TestConceptsLatent tuberculosis infectionInflammatory bowel diseaseTuberculin skin testBiologic therapyLTBI treatmentIBD patientsTuberculosis reactivationBowel diseaseTuberculosis infectionLTBI treatment regimenReactivation of TBRisk of reactivationInterferon-gamma releaseOutcome of treatmentStudy inclusion criteriaMedian annual riskAdalimumab monotherapyIsoniazid therapyTB reactivationCertolizumab pegolPrimary outcomeRetrospective reviewTreatment regimenMedian timeGamma release
2014
Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C
Al-Bawardy B, Kim WR, Poterucha JJ, Gross JB, Charlton MR, Larson JJ, Colby CL, Canterbury K, Warner J, Therneau TM. Comparative Effectiveness of Telaprevir-Based Triple Therapy in Patients With Chronic Hepatitis C. Mayo Clinic Proceedings 2014, 89: 595-601. PMID: 24661475, PMCID: PMC4160303, DOI: 10.1016/j.mayocp.2014.01.024.Peer-Reviewed Original ResearchConceptsRapid virologic responseChronic hepatitis CVirologic responseEarly virologic responseTriple therapyDual therapyHepatitis CP-IFNSustained virologic responseTreatment response categoriesTreatment-naive patientsPhase 3 trialRBV dose reductionPrior nonresponsePrior relapseCirrhosis statusProspective databaseViral hepatitisHemoglobin levelsAntiviral therapyWeek 4Dose reductionMean decreaseEligibility criteriaPatients